Indian Journal of Drugs and Diseases

Open Access Open Access  Restricted Access Subscription Access

Review on Gastroretentive Drug Delivery Systems


Affiliations
1 Department of pharmaceutics, B. M. Shah College of Pharmaceutical Education and Research, Modasa, District- Sabarkantha, Gujarat, India
 

Controlled release (CR) dosage forms have been extensively used to improve therapy with several important drugs. Incorporation of the drug in a controlled release gastroretentive dosage forms (CR-GRDF) which can remain in the gastric region for several hours would significantly prolong the gastric residence time of drugs and improve bioavailability, reduce drug waste, and enhance the solubility of drugs that are less soluble in high pH environment. Several approaches are currently utilized in the prolongation of the GRT, including floating drug delivery systems (FDDS), swelling and expanding systems, and polymeric bioadhesive systems, high-density systems, modified-shape systems and other delayed gastric emptying devices. In this review, current&recently developments of Stomach Specific FDDS are discussed that helps to overcome physiological adversities like short gastric residence times and unpredictable gastric emptying times

Keywords

Floating Drug Delivery Systems, Gastric Residence Time, Effervescent, Noneffervescent
User
Notifications

  • Vyas SP and Roop K Khar (year.?) Controlled drug delivery, concepts & advances Vallabh Prakashan. pp: 196-217

  • Jain NK (2004) Progress in controlled & novel drug delivery systems, 1st edn, CBS Publishers. pp: 76-97

  • Chawla G, Gupta P, Koradia V, Bansal AK (2003) Pharmaceutical Technology.pp: 50-68

  • Shweta Arora, Javed Ali, Alka Ahuja and Roop K Khar (2005) Floating drug delivery. Systems- A Reviews. Aaps. Pharm.Sci.Tech. 6(3), E372-E390

  • Desai S and Bolton S (1993) A floating controlled release drug delivery system: in vitro- in vivo evaluation. Pharm. Res. 10, 1321-1325. PubMed DOI: 10.1023/A: 1018921830385

  • Singh BN and Kim KH (2000) Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control Release. 63, 235-259. PubMed DOI: 10.1016/S0168-3659(99)00204- 7

  • Caldwell LJ, Gardner CR and Cargill RC (1988) Drug delivery device which can be retained in the stomach for a controlled period of time, US Patent No. 4735804

  • Gupta P, Vermani K, and Garg S (2002) Hydrogels: From controlled release to pH responsive drug delivery . Drug Discov. Today 7(10), 569- 579.

  • Deshpande AA et al. (1997) Development of a novel controlled-release system for gastric retention .Pharm. Res. 14(6), 815-819

  • Ito R, Machida Y, Sannan T and Nagai T (1990) Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration. Int. J. Pharm. 61 (1-2), 109-117

  • Hwang SJ, Park H and Park K (1998) Gastric retentive drugdelivery systems. Crit. Rev. Ther. Drug Carr. Syst. 15(3), 243-284.

  • Clarke GM, Newton JM and Short MD (1993) Gastrointestinal transit of pellets of differing size and density. Int. J. Pharm. 100 (1-3), 81-92.

  • Clarke GM, Newton JM and Short MD (1995) Comparative gastrointestinal transit of pellet systems of varying density. Int. J. Pharm. 114 (1), 1-11

  • Talukdar R and Fassihi R (2004) Gastroretentive delivery systems: hollow beads. Drug Dev. Ind. Pharm. 30, 405-412

  • Hilton AK and Deasy PB (1992) In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxicillin trihydrate. Int. J .Pharm. 86, 79-88

  • Seth PR and Tossounian J (1984) The hydrodynamically balanced system, a novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 10, 313-339.

  • Hwang SJ, Park H, Park K. Gastroretentive delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 15(3), 243-284

  • Reddy LH and Murthy RS (2002). Floating dosage system in drug delivery. Crit Rev Ther Drug Carrier Syst 2002; 19(6): 553-85.

  • Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC and Falson F (2006) Gastroretentive dosage forms: overview and special case of Helicibacter pylori. J. Control Release. 111, 1-18

  • Kawashima Y, Niwa T, Takenchi H, Hino T and Itoh Y (1992) Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci. 81, 135-140.

  • Whiteland L, Fell JT and Collett JH (1996) Development of gastroretentive dosage form. Eur. J. Pharm. Sci. 4(suppl.), S182.

  • Harrigan RM (1977) Drug delivery device for preventing contact of undissolved drug with the stomach lining. US Patent 405 5178; October 25, 1977.

  • Vyas SP and Khar RK (2006) Gastroretentive systems. In: Controlled drug Delivery. Vallabh Prakashan, Delhi, India. pp: 197-217

  • Garg R and Gupta GD (2008) Progress in controlled gastroretentive delivery systems. Trop. J. Pharm. Res. 7(3), 1055-1066.

  • Timmermans J and Moes AJ (1994) Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J. Pharm. Sci. 83, 8-24.

  • Timmermans and Moes AJ (1990) How well do floating dosage forms float?. Int. J.Pharm.62, 207-216

  • Seth PR and Tossounian J (1984) The hydrodynamically balanced systemHBSTM: A novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 10, 313-339.

  • Yeole PG, Khan S and Patel VF (2005) Floating drug delivery systems: Need and development. Indian. J. Pharm. Sci. 67(3), 265-272

  • Gupta PK and Robinson JR (1992) Oral controlled- release delivery, in treatise on controlled drug delivery, A. Kydonieus, Eds., Marcel Dekker, New Jersey. pp: 255-310

  • Park K and Robinson JR (1984) Bioadhesive polymers as platforms for oral- controlled drug delivery: Method to study bioadhesion. Int. J. Pharm. 19(1), 107-127.

  • www.pharmacoinfo.net.

  • Desai S and Bolton SA (1993) Floating controlled release system: In‐vitro -In‐vivo evaluation. Pharm. Res. 10, 1321‐1325.

  • Patel VF, Patel NM and Yeole PG (2005) Studies on formulation and evaluation Ranitidine floating tablets. Ind. J. Pharm. Sci. 67(6), 703‐709

  • Burns SJ, Corness D and Hay G (1995) Development and validation of an in vitro dissolution method for a floating dosage form with biphasic release characteristics. Int. J. Pharm. 121, 37-34

  • Timmermans J and Andre JM (1994) Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J. Pharm. Sci. 83,18Y24.

  • Arrora S, Ali J, Khar RK and Baboota S (2005) Floatng drug delivery systems: A review. AAPS Pharm. Sci. Tech. 6(3) 372-90

  • Vyas SP and Khar RK (2006) Gastroretentive systems. In: Controlled drug Delivery. Vallabh Prakashan, Delhi, India. pp:197-217

  • Chawla G, Gupta P and Bansal AK (2004) Gastroretentive drug delivery systems. In: Jain NK editor. Progress in controlled and novel drug delivery systems. CBS Publishers and Distributors. New Delhi. pp: 76-97

  • Pillay V and Fassihi R (1998) Evaluation and comparision of dissolution data derived from different modified release dosage forms: an alternative method. J. Control Release. 55,45-55


Abstract Views: 523

PDF Views: 1893




  • Review on Gastroretentive Drug Delivery Systems

Abstract Views: 523  |  PDF Views: 1893

Authors

Parth Chauhan
Department of pharmaceutics, B. M. Shah College of Pharmaceutical Education and Research, Modasa, District- Sabarkantha, Gujarat, India
M. S. Patel
Department of pharmaceutics, B. M. Shah College of Pharmaceutical Education and Research, Modasa, District- Sabarkantha, Gujarat, India
N. M. Patel
Department of pharmaceutics, B. M. Shah College of Pharmaceutical Education and Research, Modasa, District- Sabarkantha, Gujarat, India

Abstract


Controlled release (CR) dosage forms have been extensively used to improve therapy with several important drugs. Incorporation of the drug in a controlled release gastroretentive dosage forms (CR-GRDF) which can remain in the gastric region for several hours would significantly prolong the gastric residence time of drugs and improve bioavailability, reduce drug waste, and enhance the solubility of drugs that are less soluble in high pH environment. Several approaches are currently utilized in the prolongation of the GRT, including floating drug delivery systems (FDDS), swelling and expanding systems, and polymeric bioadhesive systems, high-density systems, modified-shape systems and other delayed gastric emptying devices. In this review, current&recently developments of Stomach Specific FDDS are discussed that helps to overcome physiological adversities like short gastric residence times and unpredictable gastric emptying times

Keywords


Floating Drug Delivery Systems, Gastric Residence Time, Effervescent, Noneffervescent

References